Last updated: September 4, 2026
Sotorasib, marketed as Lumakras by Amgen, established the first FDA-approved treatment for KRAS G12C-mutated locally advanced or metastatic non-small-cell lung cancer (NSCLC). Its commercial performance has been weaker than the initial biomarker opportunity suggested. Annual sales increased from $169 million in 2021 to $285 million in 2022, then declined to approximately $269 million in 2023 as adagrasib entered the market, treatment sequencing became more competitive and confirmatory-trial data failed to show an overall-survival advantage.[1]
The asset remains commercially relevant because KRAS G12C is a validated oncology target and sotorasib has a regulatory position in previously treated NSCLC. Its principal risks are modest market penetration, competition from adagrasib, limited use outside later-line therapy, emerging first-line combination strategies and eventual generic exposure after core patent protection expires.
What is sotorasib and how large is its addressable market?
Sotorasib is an oral, irreversible KRAS G12C inhibitor. KRAS G12C occurs in about 13% of lung adenocarcinomas, with lower prevalence in colorectal cancer and other solid tumors.[2]
The FDA approved Lumakras in May 2021 for adults with KRAS G12C-mutated locally advanced or metastatic NSCLC after at least one prior systemic therapy. The approval was initially accelerated and was based primarily on the CodeBreaK 100 trial.[3] The FDA converted the indication to traditional approval in December 2022 after the confirmatory CodeBreaK 200 trial demonstrated a progression-free-survival benefit.[4]
Sotorasib regulatory milestones
| Date |
Event |
| May 2021 |
FDA accelerated approval for previously treated KRAS G12C-mutated NSCLC |
| May 2021 |
Commercial launch of Lumakras in the United States |
| December 2022 |
FDA traditional approval following CodeBreaK 200 |
| December 2022 |
FDA approval of adagrasib, creating direct competition |
| 2023 |
Continued commercial use primarily in later-line NSCLC |
| 2024 |
Market remained concentrated in previously treated KRAS G12C-positive NSCLC |
The practical U.S. patient pool is smaller than the prevalence estimate suggests. Patients must have a confirmed KRAS G12C mutation, advanced disease, prior systemic treatment and sufficient clinical status for oral targeted therapy. Testing rates, rapid disease progression and competition from immunotherapy-based regimens reduce the treated population.
How effective is sotorasib compared with adagrasib?
Sotorasib and adagrasib are the two approved KRAS G12C inhibitors in the U.S. Their efficacy is broadly comparable in later-line NSCLC, but their clinical profiles differ.
| Metric |
Sotorasib |
Adagrasib |
| Brand |
Lumakras |
Krazati |
| Sponsor |
Amgen |
Bristol Myers Squibb |
| FDA NSCLC approval |
May 2021 |
December 2022 |
| Initial regulatory pathway |
Accelerated approval |
Accelerated approval |
| Confirmatory evidence |
CodeBreaK 200 |
KRYSTAL-12 |
| Median PFS in confirmatory study |
5.6 months |
Approximately 6.5 months |
| Objective response rate |
28% |
Approximately 33% |
| Main commercial position |
Later-line NSCLC |
Later-line NSCLC |
| Key safety issues |
Diarrhea, hepatotoxicity, nausea |
Gastrointestinal toxicity, QT prolongation, hepatotoxicity |
CodeBreaK 200 showed median progression-free survival of 5.6 months with sotorasib versus 4.5 months with docetaxel. The objective response rate was 28% versus 13%.[4] Overall survival was not statistically superior after adjustment for crossover and other trial factors. This limited the ability of the trial to support broad treatment migration into earlier lines.
Adagrasib benefits from longer dosing flexibility and clinical development in colorectal cancer combinations, but it also has gastrointestinal and cardiac monitoring requirements. Neither drug has established an unambiguous efficacy advantage that eliminates the other from the market.
What is the financial trajectory of Lumakras?
Lumakras revenue has followed a launch-and-plateau pattern rather than the rapid growth expected from a first-in-class targeted oncology product.
| Fiscal year |
Lumakras sales |
Year-over-year change |
| 2021 |
$169 million |
New product |
| 2022 |
$285 million |
69% |
| 2023 |
Approximately $269 million |
Approximately -6% |
Amgen reported the 2021 and 2022 figures in its annual filings. The 2023 result reflected a decline in demand and competitive pressure despite the conversion to traditional FDA approval.[1,5]
Why did Lumakras sales flatten?
The primary factors are:
- Sotorasib is mainly used after progression on platinum chemotherapy and immunotherapy, limiting treatment duration and patient volume.
- Adagrasib entered the market with a competing KRAS G12C label.
- CodeBreaK 200 established a PFS benefit but did not demonstrate a clear overall-survival advantage.
- Hepatotoxicity can complicate use after immune-checkpoint inhibitor therapy.
- Many patients progress rapidly and do not reach a KRAS-targeted treatment line.
- Treatment sequencing remains physician-dependent because there is no definitive head-to-head trial against adagrasib.
The product’s revenue base is meaningful for a single indication but immaterial relative to Amgen’s total sales. Amgen generated $28.2 billion in total revenue in 2023, making Lumakras approximately 1% of company sales.[1] The drug is therefore strategically important for oncology presence and pipeline validation, but it is not a major company-wide earnings driver.
What is the FDA and Orange Book status of sotorasib?
Lumakras is FDA-approved as a prescription tablet. Its U.S. indication is restricted to adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC who received at least one prior systemic therapy.
The FDA approval requires use of an FDA-approved test for identifying KRAS G12C mutations. The indication is not a broad approval for all KRAS-mutated cancers.
The Orange Book contains patent listings for the approved product and its use. The relevant protection categories include:
- Sotorasib composition-of-matter protection.
- Pharmaceutical composition and tablet formulation protection.
- Methods of treating KRAS G12C-mutated cancers.
- Dosage and administration claims.
- Potential manufacturing and solid-form claims.
The core composition patent is expected to provide protection into the early 2030s, subject to patent-term adjustment, patent-term extension and pediatric exclusivity. Later formulation and method-of-use patents can create additional barriers, but their practical value depends on whether generic applicants can design around them.
No publicly prominent Paragraph IV challenge had produced an established U.S. generic launch pathway for sotorasib through the end of 2024. The absence of a visible challenge reduces near-term generic-entry pressure, but it does not remove litigation risk. A generic applicant can file an abbreviated new drug application with a Paragraph IV certification before all listed patents expire.
When does sotorasib lose exclusivity?
The likely commercial exclusivity sequence is:
| Protection category |
Expected effect |
| FDA regulatory exclusivity |
Initial approval protection ended or was substantially reduced after confirmatory approval |
| Core chemical patent |
Primary protection expected into the early 2030s |
| Pediatric exclusivity |
Could add six months if granted |
| Formulation and method patents |
May extend selected claims beyond core composition protection |
| Generic entry |
Possible after successful Paragraph IV litigation, settlement or patent expiry |
The most important date for investors is not the latest nominal patent expiration. It is the earliest date on which a competent generic manufacturer can launch without infringing enforceable claims. A successful Paragraph IV challenge could accelerate entry by several years. Conversely, a valid formulation or method-of-use patent may delay launch even after the composition patent expires.
Because patent listings and term calculations can change, the FDA Orange Book and USPTO Patent Center are the controlling sources for a transaction or litigation decision.[6,7]
What patent litigation and Paragraph IV risks affect Lumakras?
No major public settlement between Amgen and a generic sotorasib manufacturer had defined a market-entry date through the end of 2024. The absence of a reported settlement is favorable to Amgen’s near-term exclusivity position.
The main litigation scenarios are:
Paragraph IV challenge to the composition patent
This is the highest-impact challenge. If a generic defeats the core composition claims, the market could face rapid erosion because oral small-molecule oncology drugs are relatively straightforward to copy once active-ingredient and bioequivalence requirements are met.
Challenge to formulation patents
A generic may argue that it does not infringe tablet, excipient, solid-form or manufacturing claims. Formulation patents are usually narrower than composition patents and may offer weaker protection if alternative formulations are available.
Method-of-use litigation
A generic applicant may use a skinny-label strategy that omits the patented KRAS G12C NSCLC indication. This could limit induced-infringement exposure, although prescribing behavior and product labeling can complicate the analysis.
Settlement risk
A settlement could establish a confidential or public launch date before patent expiry. There was no widely reported, market-defining sotorasib settlement through the end of 2024.
What competitive forces determine sotorasib’s market share?
The competitive landscape includes direct KRAS G12C inhibitors, alternative targeted therapies and broader NSCLC treatment regimens.
Direct competitors
Adagrasib is the principal direct competitor. It is marketed by Bristol Myers Squibb following the company’s acquisition of Mirati Therapeutics. The transaction gave Bristol Myers Squibb a commercial oncology platform and direct access to the KRAS G12C market.
Indirect competitors
Sotorasib competes for treatment sequencing against:
- Platinum chemotherapy.
- PD-1 and PD-L1 inhibitors.
- Docetaxel-based regimens.
- Antibody-drug conjugates.
- Clinical trials of next-generation KRAS inhibitors.
- Combination regimens designed to delay resistance.
The market could expand if KRAS G12C inhibitors demonstrate convincing first-line activity, combination efficacy or use in colorectal cancer. It could contract if resistance emerges quickly, toxicity limits duration or competing agents achieve better central nervous system activity.
What licensing and corporate transactions affect sotorasib?
Amgen acquired Array BioPharma in 2019 for approximately $10.5 billion. Array had a portfolio of oncology assets and discovery capabilities, while Amgen provided global commercial scale and development infrastructure.[8]
Sotorasib was developed within Amgen’s oncology program with technology and discovery capabilities associated with the Array transaction. The deal increased Amgen’s exposure to precision oncology but also raised the financial hurdle for the asset portfolio as a whole.
No separate licensing transaction has become as commercially important to Lumakras as the Amgen-Array acquisition. Amgen retains the central commercial and development role for sotorasib.
How strong is the sotorasib patent and commercial estate?
The estate is moderately strong, not unassailable.
Strengths
- Validated KRAS G12C target.
- FDA traditional approval in a defined NSCLC population.
- Core small-molecule composition protection.
- Established manufacturing and distribution.
- First-mover physician familiarity.
- Molecular testing infrastructure already exists.
Weaknesses
- Narrow treatment-line positioning.
- Direct competition from adagrasib.
- Limited differentiation on overall survival.
- Potential hepatotoxicity after immunotherapy.
- Small revenue base relative to Amgen’s oncology infrastructure.
- Generic substitution risk after core protection weakens.
The commercial estate is stronger than the clinical differentiation. Amgen’s principal defense is the combination of patent duration, physician familiarity, payer coverage and ongoing clinical development rather than a clear superiority claim.
What generic launch scenarios exist for sotorasib?
Three scenarios are commercially relevant.
| Scenario |
Timing |
Market impact |
| No early Paragraph IV challenge |
Near-term |
Amgen retains essentially the full U.S. market until core patent expiry |
| Successful Paragraph IV challenge |
Several years before expiry |
Rapid price and volume erosion |
| Entry after core patent expiry |
Early 2030s or later |
High substitution risk, with limited brand retention |
Small-molecule oncology products commonly experience steep price declines after generic entry. The extent of erosion would depend on the number of approved ANDAs, payer substitution rules and whether Amgen retains enforceable formulation or method claims.
A 2020s launch of a meaningfully improved next-generation KRAS inhibitor could create earlier commercial erosion without patent litigation.
How does sotorasib compare with other Amgen oncology assets?
Lumakras is smaller than Amgen’s mature inflammation, bone-health and cardiovascular products. Its strategic value is tied to precision oncology and future KRAS combinations, not current revenue scale.
| Product |
Therapeutic area |
Commercial profile |
| Lumakras |
KRAS G12C NSCLC |
Small but strategically important oncology asset |
| Xgeva |
Bone metastases and skeletal events |
Mature oncology franchise |
| Prolia |
Osteoporosis |
Large established product |
| Repatha |
Cardiovascular disease |
Large growth and access-driven franchise |
| Blincyto |
Hematologic oncology |
More diversified oncology platform |
Lumakras does not materially change Amgen’s consolidated financial risk. Its commercial underperformance matters more for the return on the Array acquisition and Amgen’s precision-oncology strategy.
Key Takeaways
- Sotorasib is the first FDA-approved KRAS G12C inhibitor and remains approved for previously treated KRAS G12C-mutated NSCLC.
- Lumakras revenue rose from $169 million in 2021 to $285 million in 2022, then declined to approximately $269 million in 2023.
- Adagrasib is the main direct competitor and limits pricing power and market expansion.
- CodeBreaK 200 confirmed a progression-free-survival benefit but did not establish a clear overall-survival advantage.
- Core patent protection is expected to reach into the early 2030s, with additional risk determined by formulation, method-of-use and manufacturing claims.
- No major public Paragraph IV settlement had established a generic launch date through the end of 2024.
- The largest commercial upside would come from successful earlier-line or combination indications.
- The largest downside risks are direct KRAS competition, rapid resistance, treatment-line constraints and early generic challenge.
FAQs
Is sotorasib still commercially relevant after adagrasib approval?
Yes. Sotorasib retains FDA approval, physician familiarity and an established safety and supply infrastructure. Its market share is constrained, but the product remains a viable later-line therapy.
Does sotorasib have an FDA-approved colorectal cancer indication?
Through the end of 2024, sotorasib’s principal U.S. FDA indication was KRAS G12C-mutated advanced NSCLC. Colorectal cancer development has focused heavily on combinations, particularly EGFR-directed regimens.
Is sotorasib a biologic or a generic drug?
Sotorasib is a small-molecule prescription drug, not a biologic. Future competitors would generally seek approval through the ANDA pathway rather than the biosimilar pathway.
What is the main clinical weakness of sotorasib?
Its main weakness is limited use in previously treated disease combined with modest durability and hepatotoxicity concerns after immune-checkpoint inhibitor exposure. These factors restrict treatment duration and market size.
Could Amgen extend Lumakras exclusivity beyond the core chemical patent?
Potentially. Formulation, solid-form, manufacturing and method-of-use patents can extend enforceable protection for specific claims. Their value depends on validity, infringement and whether a generic can use a non-infringing formulation or label.
References
- Amgen Inc. (2024). 2023 annual report. Thousand Oaks, CA: Author.
- Skoulidis, F., & Heymach, J. V. (2019). Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nature Reviews Cancer, 19(9), 495-509.
- U.S. Food and Drug Administration. (2021, May 28). FDA grants accelerated approval to sotorasib for KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer.
- de Langen, A. J., Johnson, M. L., Mazieres, J., et al. (2023). Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: A randomised, open-label, phase 3 trial. The Lancet, 401(10378), 733-746.
- Amgen Inc. (2023). 2022 annual report. Thousand Oaks, CA: Author.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. Silver Spring, MD: Author.
- United States Patent and Trademark Office. (2024). Patent Center. Alexandria, VA: Author.
- Amgen Inc. (2019, June 17). Amgen to acquire Array BioPharma for $10.5 billion. Thousand Oaks, CA: Author.
